Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Spratlin, Jennifer L., Mulder, Karen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189759/
https://www.ncbi.nlm.nih.gov/pubmed/22016635
http://dx.doi.org/10.3390/ijms12095895
_version_ 1782213503654821888
author Spratlin, Jennifer L.
Mulder, Karen E.
author_facet Spratlin, Jennifer L.
Mulder, Karen E.
author_sort Spratlin, Jennifer L.
collection PubMed
description The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.
format Online
Article
Text
id pubmed-3189759
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-31897592011-10-20 Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma Spratlin, Jennifer L. Mulder, Karen E. Int J Mol Sci Review The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation. Molecular Diversity Preservation International (MDPI) 2011-09-14 /pmc/articles/PMC3189759/ /pubmed/22016635 http://dx.doi.org/10.3390/ijms12095895 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Spratlin, Jennifer L.
Mulder, Karen E.
Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
title Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
title_full Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
title_fullStr Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
title_full_unstemmed Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
title_short Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma
title_sort looking to the future: biomarkers in the management of pancreatic adenocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189759/
https://www.ncbi.nlm.nih.gov/pubmed/22016635
http://dx.doi.org/10.3390/ijms12095895
work_keys_str_mv AT spratlinjenniferl lookingtothefuturebiomarkersinthemanagementofpancreaticadenocarcinoma
AT mulderkarene lookingtothefuturebiomarkersinthemanagementofpancreaticadenocarcinoma

Ejemplares similares